Richmond Pharmacology is excited to confirm our attendance at AHA Scientific Sessions 2025, hosted by the American Heart Association in New Orleans from 8–10 November.

Representing Richmond at AHA 2025:

  • Dr Jörg Täubel, Chief Executive Officer
  • Miquel Serna Pascual, PHD Representative

We look forward to connecting with attendees to discuss Richmond’s expertise in:

  • Early-phase cardiovascular and cardiometabolic research
  • First-in-human and dose-ranging studies
  • Novel biomarkers and digital endpoints
  • Regulatory engagement and global trial delivery
  • Patient-first strategies in complex CV trials

If you’re attending AHA 2025 and seeking a clinical development partner with cardiovascular expertise, arrange a meeting with us: info@richmondpharmacology.com

Learn more: AHA 2025 | American Heart Association's Scientific Sessions

‍

‍

Latest news

Leadership Spotlight - Head of Pharmacovigilance

November 16, 2026
Amina Ghareeb on Building Richmond's Pharmacovigilance Expertise
Read more

Upcoming Event

JSCPT 2026

27 - 28 November 2026
Richmond Pharmacology is excited to join the JSCPT Annual Meeting 2026 in Tokyo, Japan, on 27-28 November 2026.
View event